Skip to main content

Table 1 Inhibitors identified in the kinase inhibitor screen

From: Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer

Inhibitor Inhibitory Effect ± SD (%) Target(s)
T47D 182R-1 182R-2
Barasertib 28.2 ± 1.7 58.9 ± 2.2 59.9 ± 2.1 Aurora B
PHA-680632 23.5 ± 7.4 62.8 ± 2.7 56.1 ± 5.0 Aurora A/B/C
SNS-314 Mesylate 19.4 ± 1.5 47.0 ± 2.6 52.8 ± 5.1 Aurora A/B/C
ZM-447439 24.2 ± 6.1 57.7 ± 1.8 65.6 ± 1.5 Aurora A/B/C
CCT129202 20.1 ± 13.2 44.5 ± 4.8 48.8 ± 4.3 Aurora A/B/C
AMG 900 25.3 ± 3.0 55.8 ± 4.5 55.5 ± 0.6 Aurora A/B/C
JNJ-7706621 1.7 ± 5.7 27.5 ± 4.9 33.4 ± 4.8 Aurora A/B, cyclin A/CDK2, cyclin E/CDK2, cyclin B/CDK1
AT9283 6.2 ± 3.6 46.4 ± 2.5 52.6 ± 2.1 Aurora A/B, JAK2/3 and Abl
ENMD-2076 24.3 ± 16.5 61.8 ± 2.8 65.7 ± 1.5 Aurora A/B, Flt3/4, SFKs and VEGFR2
AZD7762 8.6 ± 10.3 30.3 ± 1.1 33.8 ± 2.8 Chk1/2
CX-4945 8.2 ± 2.1 27.9 ± 1.7 21.8 ± 1.7 CK2
PF-562271 1.4 ± 4.5 19.0 ± 3.5 14.8 ± 2.5 FAK and Pyk2
Nintedanib 11.8 ± 3.0 42.2 ± 3.5 33.9 ± 6.2 FGFR, VEGFR, PDGRF and SFKs
Dasatinib 18.0 ± 3.5 47.1 ± 2.7 37.0 ± 3.4 SFKs, Abl and c-Kit
TG100-115 5.0 ± 1.5 12.9 ± 2.3 13.2 ± 5.3 PI3Kγ/δ
  1. The growth inhibitory effect of the kinase inhibitors compared with untreated cells ± standard deviation (SD). Abbreviations: Abelson (Abl), Casein kinase (CK), checkpoint kinase (Chk), cyclin-dependent kinases (CDK), fibroblast growth factor receptor (FGFR), Fms-like Tyrosine Kinase (Flt), focal adhesion kinase (FAK), janus kinase (JAK), platelet-derived growth factor receptor (PDGFR), proline-rich tyrosine kinase (Pyk), Src Family kinases (SFKs), vascular endothelial growth factor receptor (VEGFR), and phosphoinositide 3-kinase (PI3K).